[go: up one dir, main page]

WO2012053758A3 - 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 - Google Patents

실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 Download PDF

Info

Publication number
WO2012053758A3
WO2012053758A3 PCT/KR2011/007441 KR2011007441W WO2012053758A3 WO 2012053758 A3 WO2012053758 A3 WO 2012053758A3 KR 2011007441 W KR2011007441 W KR 2011007441W WO 2012053758 A3 WO2012053758 A3 WO 2012053758A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
liver diseases
pharmaceutical composition
active ingredient
alcoholic liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/007441
Other languages
English (en)
French (fr)
Other versions
WO2012053758A2 (ko
Inventor
김종연
은종렬
이윤주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yeungnam University
Original Assignee
Industry Academic Cooperation Foundation of Yeungnam University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Yeungnam University filed Critical Industry Academic Cooperation Foundation of Yeungnam University
Priority to US13/880,792 priority Critical patent/US20130267558A1/en
Publication of WO2012053758A2 publication Critical patent/WO2012053758A2/ko
Publication of WO2012053758A3 publication Critical patent/WO2012053758A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물에 관한 것으로, 특히 상기 실로스타졸은 TNF-α 및 지방산 합성 효소인 FAS 유전자의 발현 수준을 농도의존적으로 억제할 뿐 아니라, 카스파제-3 활성을 유의적으로 억제함으로써 종래 알코올성 간염 치료제로 사용되어 오던 펜톡시필린보다 탁월한 알코올성 간질환, 특히 알코올성 간염 치료 또는 예방 효과를 나타내므로, 알코올성 간염 치료 또는 예방용 약제로서 유용하게 이용될 수 있다.
PCT/KR2011/007441 2010-10-22 2011-10-07 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 Ceased WO2012053758A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/880,792 US20130267558A1 (en) 2010-10-22 2011-10-07 Pharmaceutical composition for treating or preventing alcoholic liver diseases, containing cilostazol as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100103656A KR101094934B1 (ko) 2010-10-22 2010-10-22 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물
KR10-2010-0103656 2010-10-22

Publications (2)

Publication Number Publication Date
WO2012053758A2 WO2012053758A2 (ko) 2012-04-26
WO2012053758A3 true WO2012053758A3 (ko) 2012-06-14

Family

ID=45506428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007441 Ceased WO2012053758A2 (ko) 2010-10-22 2011-10-07 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물

Country Status (3)

Country Link
US (1) US20130267558A1 (ko)
KR (1) KR101094934B1 (ko)
WO (1) WO2012053758A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3220901B1 (en) 2014-11-20 2020-02-19 VIB vzw Means and methods for treatment of early-onset parkinson's disease
US10588906B2 (en) * 2017-08-08 2020-03-17 Seoul National University Hospital Method of preventing hair loss or promoting hair growth by using phosphodiesterase 3 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061648A1 (en) * 2002-01-25 2003-07-31 Diamedica Inc. Use of cholinesterase antagonists to treat insulin resistance
WO2009008539A1 (en) * 2007-07-11 2009-01-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives including cilostazol for treating fatty liver

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061648A1 (en) * 2002-01-25 2003-07-31 Diamedica Inc. Use of cholinesterase antagonists to treat insulin resistance
WO2009008539A1 (en) * 2007-07-11 2009-01-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives including cilostazol for treating fatty liver

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUJITA K. ET AL.: "Effectiveness of antiplatelet drugs against experiemental non-aoholic fatty liver disease", GUT, vol. 57, no. 11, 2008, pages 1583 - 1591 *

Also Published As

Publication number Publication date
US20130267558A1 (en) 2013-10-10
KR101094934B1 (ko) 2011-12-15
WO2012053758A2 (ko) 2012-04-26

Similar Documents

Publication Publication Date Title
HK1204271A1 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2009105774A3 (en) Amino acid inhibitors of cytochrome p450
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2010032140A3 (en) Pharmaceutical compositions and related methods of delivery
WO2017059223A3 (en) Compositions and methods for inhibiting gene expression of lpa
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
HK1211867A1 (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2011107755A3 (en) Immediate/delayed drug delivery
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2011051354A3 (en) Transdermal pharmaceutical compositions comprising active agents
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BRPI0819719A8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2011159129A3 (ko) 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
MX354073B (es) Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico.
HK1217495A1 (zh) 治疗活性的作为17β-羟基类固醇脱氢酶抑制剂的17-氮取代雌三烯噻唑衍生物
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
WO2011103920A3 (en) Pharmaceutical or neutraceutical formulation
WO2009045053A3 (en) A cancer sensitizer comprising chlorogenic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11834558

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13880792

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11834558

Country of ref document: EP

Kind code of ref document: A2